|
**Overview**: Amenorrhea Profile**Introduction**: The Amenorrhea Profile is a diagnostic tool designed for comprehensive amenorrhea screening using serum samples. In India, amenorrhea affects 3-5 percent of women of reproductive age, with secondary amenorrhea being more common due to polycystic ovary syndrome (PCOS, affecting 20-30 percent of women in urban studies), nutritional deficiencies, stress, thyroid disorders, hyperprolactinemia, and hypothalamic issues. Prevalence is higher in rural and low-SES groups due to malnutrition, anemia, and delayed healthcare access, leading to infertility, metabolic complications, and psychological distress. Symptoms include absence of menstruation, hirsutism, weight gain, galactorrhea, or hot flashes. High morbidity from underdiagnosis, cultural stigma around menstrual issues, limited endocrinology/gynaecology access in rural areas, and delayed treatment causing long-term infertility or osteoporosis. Per ICMR and Indian Society of Endocrinology guidelines, the test employs spectrophotometry and immunoassay for detailed hormonal analysis over 1-2 days with high sensitivity/specificity, valuable for initial evaluation in amenorrhea cases. This diagnostic falls under hormonal disorder screening and targets women with amenorrhea, addressing accurate detection of endocrine causes to guide further investigation and management. With elevated morbidity due to underdiagnosis in diverse populations, the test supports public health efforts by enabling precise identification, facilitating treatment (e.g., hormone replacement, ovulation induction), and reducing complications like infertility or metabolic syndrome. Its serum-based approach ensures reliable performance in India's varied laboratory settings.**Other Names**: Amen Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology/biochemistry, compliant with 2025 standards.**Historical Milestone**: Developed for multi-hormone screening; in India, prominence with rising PCOS and infertility awareness.**Purpose**: The test screens for 6 parameters including LH and FSH to guide amenorrhea assessment, evaluate hormonal imbalances, inform further endocrine evaluation and treatment.**Test Parameters**: 1. LH, 2. FSH, 3. Prolactin, 4. TSH, 5. Free T4, 6. Estradiol.**Pretest Condition**: Fasting 10-12 hours recommended; patients should report menstrual irregularities, weight changes, hirsutism, galactorrhea, or infertility concerns.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on menstrual history (primary/secondary), weight changes, hirsutism, galactorrhea, stress, medications, family history of endocrine disorders, or previous pregnancies.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated amenorrhea including infertility or metabolic issues, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry and immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent stress/medications can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible hormonal causes, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: Gynecologists or endocrinologists should be consulted for case management, treatment planning, and coordination with reproductive health programs.**Additional Supporting Tests**: Pelvic ultrasound, progesterone challenge, or karyotyping for confirmation.**Test Limitations**: The test may miss non-hormonal causes (e.g., Asherman syndrome) or require cycle timing; comprehensive approach with clinical correlation required.**References**: Indian Journal of Endocrinology 2024, PCOS and Amenorrhea Studies India 2023. |
